| 1 |
Gee YJ, Sea YL, Lal SK. Viral modulation of lipid rafts and their potential as putative antiviral targets. Rev Med Virol 2023;33:e2413. [PMID: 36504273 DOI: 10.1002/rmv.2413] [Reference Citation Analysis]
|
| 2 |
Heidemann J, Konrad M, Roderburg C, Loosen SH, Kostev K. Association between Antihypertensive Therapy and Risk of Acute Lower Respiratory Infections (ALRI): A Retrospective Cohort Study. Healthcare (Basel) 2022;10. [PMID: 36421642 DOI: 10.3390/healthcare10112318] [Reference Citation Analysis]
|
| 3 |
Caro-codón J, Rey JR, Iniesta AM, Rosillo SO, Castrejon-castrejon S, Rodriguez-sotelo L, Garcia-veas JM, Marco I, Martinez LA, Martin-polo L, Merino C, Martinez-cossiani M, Buño A, Gonzalez-valle L, Herrero A, López-de-sá E, Merino JL. Impact of the withdrawal of renin-angiotensin-aldosterone inhibitors on mortality in COVID-19 patients. Revista Portuguesa de Cardiologia 2022. [DOI: 10.1016/j.repc.2021.06.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Liu H, Gu H, Qu H, Bao W, Li Y, Cai D. Aberrant Cholesterol Metabolic Genes Regulation in a Negative Feedback Loop Induced by an Alphacoronavirus. Front Nutr 2022;9:870680. [DOI: 10.3389/fnut.2022.870680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Labandeira-Garcia JL, Labandeira CM, Valenzuela R, Pedrosa MA, Quijano A, Rodriguez-Perez AI. Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment. Biomedicines 2022;10:502. [PMID: 35203711 DOI: 10.3390/biomedicines10020502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 6 |
Pavía López AA, Pavía Aubry V, López Jalil HA, Conde Carmona I, Ángel Juárez VM. Relación entre el sistema renina angiotensina aldosterona y las complicaciones cardiovasculares por SARS-CoV-2. Anales Médicos de la Asociación Médica del Centro Médico ABC 2022;67:34-43. [DOI: 10.35366/104366] [Reference Citation Analysis]
|
| 7 |
Gelen V, Kükürt A, Şengül E. Role of the Renin-Angiotensin-Aldosterone System in Various Disease Processes: An Overview. Renin-Angiotensin Aldosterone System 2021. [DOI: 10.5772/intechopen.97354] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 8 |
Chamata Y, Jackson KG, Watson KA, Jauregi P. Whey-Derived Peptides at the Heart of the COVID-19 Pandemic. Int J Mol Sci 2021;22:11662. [PMID: 34769093 DOI: 10.3390/ijms222111662] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 9 |
Fayol A, Livrozet M, Pereira H, Diehl JL, Lebeaux D, Arlet JB, Cholley B, Carette C, Carves JB, Czernichow S, Hauw C, Hamada SR, Jannot AS, Volle G, Masurkar N, Mirault T, Planquette B, Sanchez O, Châtellier G, Azizi M, Hulot JS. Cardiometabolic Disorders and the Risk of Critical COVID-19 as Compared to Influenza Pneumonia. J Clin Med 2021;10:4618. [PMID: 34640638 DOI: 10.3390/jcm10194618] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Rubin SJS, Falkson SR, Degner NR, Blish CA. Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California. J Clin Transl Sci 2021;5:e8. [PMID: 34611496 DOI: 10.1017/cts.2020.489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Ayeh SK, Abbey EJ, Khalifa BAA, Nudotor RD, Osei AD, Chidambaram V, Osuji N, Khan S, Salia EL, Oduwole MO, Yusuf HE, Lasisi O, Nosakhare E, Karakousis PC. Statins use and COVID-19 outcomes in hospitalized patients. PLoS One 2021;16:e0256899. [PMID: 34506533 DOI: 10.1371/journal.pone.0256899] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 12 |
Huang L, Chen Z, Ni L, Chen L, Zhou C, Gao C, Wu X, Hua L, Huang X, Cui X, Tian Y, Zhang Z, Zhan Q. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Inflammatory Response and Viral Clearance in COVID-19 Patients. Front Cardiovasc Med 2021;8:710946. [PMID: 34490373 DOI: 10.3389/fcvm.2021.710946] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 13 |
Shylesh C M S, V S A, S K K, P UD. Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe? Clin Exp Hypertens 2021;:1-10. [PMID: 34414841 DOI: 10.1080/10641963.2021.1963070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 14 |
Magdy Beshbishy A, Oti VB, Hussein DE, Rehan IF, Adeyemi OS, Rivero-Perez N, Zaragoza-Bastida A, Shah MA, Abouelezz K, Hetta HF, Cruz-Martins N, Batiha GE. Factors Behind the Higher COVID-19 Risk in Diabetes: A Critical Review. Front Public Health 2021;9:591982. [PMID: 34307267 DOI: 10.3389/fpubh.2021.591982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 15 |
Baker J, Incognito AV, Wilson RJA, Raj SR. Syncope and silent hypoxemia in COVID-19: Implications for the autonomic field. Auton Neurosci 2021;235:102842. [PMID: 34246957 DOI: 10.1016/j.autneu.2021.102842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Lin SY, Chang SS, Lin CL, Lin CC, Hsu WH, Chou CH, Chi CY, Lin CD, Tu CY, Hsu CY, Kao CH. Association between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and community-acquired pneumonia: A nationwide population propensity-score matching study. Int J Clin Pract 2021;:e14476. [PMID: 34107133 DOI: 10.1111/ijcp.14476] [Reference Citation Analysis]
|
| 17 |
Hudakova N, Hricikova S, Kulkarni A, Bhide M, Kontsekova E, Cizkova D. Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2. Pathogens 2021;10:636. [PMID: 34064300 DOI: 10.3390/pathogens10060636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 18 |
Karabacak M. COVİD-19 PANDEMİSİNİN KARDİYOVASKÜLER ETKİLERİ. SDÜ Tıp Fakültesi Dergisi 2021. [DOI: 10.17343/sdutfd.915484] [Reference Citation Analysis]
|
| 19 |
Lee HY, Ahn J, Park J, Kang CK, Won SH, Kim DW, Park JH, Chung KH, Joh JS, Bang JH, Kang CH, Oh MD, Pyun WB; Korean Society of Hypertension., National Committee for Clinical Management of Emerging Infectious Diseases. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia. Korean J Intern Med 2021;36:617-28. [PMID: 33858123 DOI: 10.3904/kjim.2020.656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Choksi TT, Zhang H, Chen T, Malhotra N. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers. Am J Nephrol 2021;52:250-60. [PMID: 33827074 DOI: 10.1159/000515232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 21 |
Nouri-Vaskeh M, Kalami N, Zand R, Soroureddin Z, Varshochi M, Ansarin K, Rezaee H, Taghizadieh A, Sadeghi A, Ahangari Maleki M, Esmailnajad A, Saleh P, Haghdoost M, Maleki M, Sharifi A. Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial. Int J Clin Pract 2021;75:e14124. [PMID: 33650197 DOI: 10.1111/ijcp.14124] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 22 |
Centurión OA, Scavenius KE, García LB, Torales JM, Miño LM. Potential Mechanisms of Cardiac Injury and Common Pathways of Inflammation in Patients With COVID-19. Crit Pathw Cardiol 2021;20:44-52. [PMID: 32467423 DOI: 10.1097/HPC.0000000000000227] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 23 |
Saha S, Chakrabarti S, Singh PK, Poddar J, Satapathi S, Saini S, Kakar SS, Roy P. Physiological Relevance of Angiotensin Converting Enzyme 2 As a Metabolic Linker and Therapeutic Implication of Mesenchymal Stem Cells in COVID-19 and Hypertension. Stem Cell Rev Rep 2021;17:132-43. [PMID: 32748331 DOI: 10.1007/s12015-020-10012-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 24 |
Ferrari F, Santos RD. Statins and COVID-19: To Suspend or Not to Suspend? That is the Question! Arq Bras Cardiol 2021;116:147-52. [PMID: 33566980 DOI: 10.36660/abc.20200949] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 25 |
Appel SJ, Wadas TM, Andrabi MS. Management of Diabetes During a Dual Pandemic. J Nurse Pract 2021;17:680-6. [PMID: 34127911 DOI: 10.1016/j.nurpra.2020.12.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 26 |
Lee HY, Ahn J, Park J, Kyung Kang C, Won SH, Wook Kim D, Park JH, Chung KH, Joh JS, Bang JH, Hee Kang C, Bum Pyun W, Oh MD; Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases. Beneficial Effect of Statins in COVID-19-Related Outcomes-Brief Report: A National Population-Based Cohort Study. Arterioscler Thromb Vasc Biol 2021;41:e175-82. [PMID: 33535790 DOI: 10.1161/ATVBAHA.120.315551] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 27 |
Cohen JB, South AM, Shaltout HA, Sinclair MR, Sparks MA. Renin-angiotensin system blockade in the COVID-19 pandemic. Clin Kidney J 2021;14:i48-59. [PMID: 33796285 DOI: 10.1093/ckj/sfab026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 28 |
Sun H, Su X, Huang L, Mu D, Qu Y. Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection. Biomolecules 2021;11:196. [PMID: 33573324 DOI: 10.3390/biom11020196] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 29 |
Vitiello A, Pelliccia C, Ferrara F. Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discov Today 2021;26:870-4. [PMID: 33486116 DOI: 10.1016/j.drudis.2021.01.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 30 |
Vitiello A, La Porta R, Ferrara F. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses 2021;147:110486. [PMID: 33460992 DOI: 10.1016/j.mehy.2021.110486] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 31 |
Tian C, Li N, Bai Y, Xiao H, Li S, Ge QG, Shen N, Ma QB. Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension. World J Clin Cases 2021; 9(1): 47-60 [PMID: 33511171 DOI: 10.12998/wjcc.v9.i1.47] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 32 |
Chu C, Zeng S, Hasan AA, Hocher CF, Krämer BK, Hocher B. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis. Br J Clin Pharmacol 2021;87:2475-92. [PMID: 33217033 DOI: 10.1111/bcp.14660] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 33 |
Lin SY, Ju SW, Lin CL, Lin CC, Hsu WH, Chou CH, Chi CY, Hsu CY, Kao CH. Risk of Viral Infection in Patients Using Either Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Nationwide Population-based Propensity Score Matching Study. Clin Infect Dis 2020;71:2695-701. [PMID: 32504531 DOI: 10.1093/cid/ciaa734] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 34 |
Centurión OA, Miño LM, Scavenius KE. Severe Acute Respiratory Syndrome Coronavirus 2: The Importance of Prompt Detection of Cardiovascular Involvement. TOCMJ 2020;14:38-41. [DOI: 10.2174/18741924020140100038] [Reference Citation Analysis]
|
| 35 |
Urbach D, Awiszus F, Leiß S, Venton T, Specht AV, Apfelbacher C. Associations of Medications With Lower Odds of Typical COVID-19 Symptoms: Cross-Sectional Symptom Surveillance Study. JMIR Public Health Surveill 2020;6:e22521. [PMID: 33197879 DOI: 10.2196/22521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 36 |
Gareeva DF, Musin TI, Pavlov VN, Davtyan PA, Ishmetov VS, Plotnikova MR, Pavlov AV, Cai B, Stricker P, Carvalho K, Zagidullin NS. Statins: unexpected help in COVID-19. Arter gipertenz 2020;26:509-517. [DOI: 10.18705/1607-419x-2020-26-5-509-517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 37 |
Hoevenaar M, Goossens D, Roorda J. Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads. J Renin Angiotensin Aldosterone Syst 2020;21:1470320320979097. [PMID: 33283602 DOI: 10.1177/1470320320979097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 38 |
Oz M, Lorke DE, Kabbani N. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. Pharmacol Ther 2021;221:107750. [PMID: 33275999 DOI: 10.1016/j.pharmthera.2020.107750] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 39 |
Martin JH, Head R. A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19. Br J Clin Pharmacol 2021;87:875-85. [PMID: 32959913 DOI: 10.1111/bcp.14551] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 40 |
Fan Y, Guo T, Yan F, Gong M, Zhang XA, Li C, He T, Luo H, Zhang L, Chen M, Wu X, Wang H, Deng KQ, Bai J, Cai L, Lu Z. Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study. Front Med (Lausanne) 2020;7:584870. [PMID: 33330541 DOI: 10.3389/fmed.2020.584870] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 41 |
Dai HL, Guang XF. COVID-19 and the pulmonary vascular injury. J Renin Angiotensin Aldosterone Syst 2020;21:1470320320972276. [PMID: 33176538 DOI: 10.1177/1470320320972276] [Reference Citation Analysis]
|
| 42 |
Kizilkaya H, Deveci M. A Case Report about Diabetes Mellitus and COVID-19 Outbreak. Düzce Tıp Fakültesi Dergisi 2020. [DOI: 10.18678/dtfd.786335] [Reference Citation Analysis]
|
| 43 |
Mahajan K, Chand Negi P, Ganju N, Sondhi S, Gaur N, Somendra R. Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts. Int J Hypertens 2020;2020:1025913. [PMID: 33145103 DOI: 10.1155/2020/1025913] [Reference Citation Analysis]
|
| 44 |
Gao YL, Du Y, Zhang C, Cheng C, Yang HY, Jin YF, Duan GC, Chen SY. Role of Renin-Angiotensin System in Acute Lung Injury Caused by Viral Infection. Infect Drug Resist 2020;13:3715-25. [PMID: 33116692 DOI: 10.2147/IDR.S265718] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 45 |
В. І. Цимбалюк, М. Д. Тронько, Ю. Г. Антипкін, В. В. Попова. Diabetes mellitus and COVID-19: current issues of pathogenesis, clinic and therapy. Literature review. RE 2020. [DOI: 10.18370/2309-4117.2020.54.8-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 46 |
Blîndu E, Gerculy R, Opincariu D, Cernica D, Benedek I. Cessation of Renin-Angiotensin System Antagonists During the SARS-CoV-2 Pandemic – Do We Have the Evidence? Journal of Interdisciplinary Medicine 2020;5:105-9. [DOI: 10.2478/jim-2020-0022] [Reference Citation Analysis]
|
| 47 |
Yan H, Valdes AM, Vijay A, Wang S, Liang L, Yang S, Wang H, Tan X, Du J, Jin S, Huang K, Jiang F, Zhang S, Zheng N, Hu Y, Cai T, Aithal GP. Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study. Clin Pharmacol Ther 2020;108:1185-94. [PMID: 32910830 DOI: 10.1002/cpt.2047] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 48 |
Christiansen CF, Heide-Jørgensen U, Rasmussen TB, Bodilsen J, Søgaard OS, Maeng M, Vistisen ST, Schmidt M, Pottegård A, Lund LC, Reilev M, Hallas J, Johansen NB, Brun NC, Sørensen HT, Thomsen RW. Renin-Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study. J Am Heart Assoc 2020;9:e017297. [PMID: 32998607 DOI: 10.1161/JAHA.120.017297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 49 |
Solnier J, Fladerer JP. Flavonoids: A complementary approach to conventional therapy of COVID-19? Phytochem Rev 2020;:1-23. [PMID: 32982616 DOI: 10.1007/s11101-020-09720-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 50 |
Yehualashet AS, Belachew TF. ACEIs and ARBs and Their Correlation with COVID-19: A Review. Infect Drug Resist 2020;13:3217-24. [PMID: 32982336 DOI: 10.2147/IDR.S264882] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 51 |
de la Cruz A, Ashraf S, Vittorio TJ, Bella JN. COVID-19 and renin-angiotensin system modulators: what do we know so far? Expert Rev Cardiovasc Ther 2020;18:743-8. [PMID: 32842817 DOI: 10.1080/14779072.2020.1814143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 52 |
Kutlutürk F. COVID-19 Pandemisi ve Diabetes Mellitus. Turkish Journal of Diabetes and Obesity 2020;4:130-7. [DOI: 10.25048/tudod.746139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 53 |
Yang Y, Liu X, Liu Y, Chen Y, Tian Y, Fu X, Zhong W, Xie C. Efficacy and safety of ACEI/ARB drugs in patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2020;99:e21723. [PMID: 32871892 DOI: 10.1097/MD.0000000000021723] [Reference Citation Analysis]
|
| 54 |
Urbach D, Awiszus F, Leiß S, Venton T, Specht AVD, Apfelbacher C. Associations of Medications With Lower Odds of Typical COVID-19 Symptoms: Cross-Sectional Symptom Surveillance Study (Preprint).. [DOI: 10.2196/preprints.22521] [Reference Citation Analysis]
|
| 55 |
Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, Persu A, Prejbisz A, Riemer TG, Wang JG, Burnier M. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res 2020;116:1688-99. [PMID: 32293003 DOI: 10.1093/cvr/cvaa097] [Cited by in Crossref: 209] [Cited by in F6Publishing: 228] [Article Influence: 69.7] [Reference Citation Analysis]
|
| 56 |
Barochiner J, Martínez R. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis. J Clin Pharm Ther 2020;45:1244-52. [PMID: 32767823 DOI: 10.1111/jcpt.13246] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 57 |
Di Micco P, Di Micco G, Russo V, Poggiano MR, Salzano C, Bosevski M, Imparato M, Fontanella L, Fontanella A. Blood Targets of Adjuvant Drugs Against COVID19. J Blood Med 2020;11:237-41. [PMID: 32694923 DOI: 10.2147/JBM.S256121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 58 |
Koliaki C, Tentolouris A, Eleftheriadou I, Melidonis A, Dimitriadis G, Tentolouris N. Clinical Management of Diabetes Mellitus in the Era of COVID-19: Practical Issues, Peculiarities and Concerns. J Clin Med 2020;9:E2288. [PMID: 32708504 DOI: 10.3390/jcm9072288] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 59 |
Ingraham NE, Barakat AG, Reilkoff R, Bezdicek T, Schacker T, Chipman JG, Tignanelli CJ, Puskarich MA. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review. Eur Respir J 2020;56:2000912. [PMID: 32341103 DOI: 10.1183/13993003.00912-2020] [Cited by in Crossref: 90] [Cited by in F6Publishing: 94] [Article Influence: 30.0] [Reference Citation Analysis]
|
| 60 |
Sarzani R, Giulietti F, Di Pentima C, Giordano P, Spannella F. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. Am J Physiol Lung Cell Mol Physiol 2020;319:L325-36. [PMID: 32639866 DOI: 10.1152/ajplung.00189.2020] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 61 |
Kalra RS, Tomar D, Meena AS, Kandimalla R. SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. Pathogens 2020;9:E546. [PMID: 32645974 DOI: 10.3390/pathogens9070546] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 62 |
Tao Guo, Yongzhen Fan, Ming Chen, Xiaoyan Wu, Lin Zhang, Tao He, Hairong Wang, Jing Wan, Xinghuan Wang, Zhibing Lu. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020;5. [PMID: 32219356 DOI: 10.1001/jamacardio.2020.1017] [Cited by in Crossref: 2516] [Cited by in F6Publishing: 2606] [Article Influence: 838.7] [Reference Citation Analysis]
|
| 63 |
Chenna A, Konala VM, Bose S, Roy S, Madhira BR, Gayam V, Naramala S, Adapa S. Acute Kidney Injury in a Case Series of Patients with Confirmed COVID-19 (Coronavirus Disease 2019): Role of Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Blockade. Case Rep Nephrol 2020;2020:8811931. [PMID: 32685221 DOI: 10.1155/2020/8811931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 64 |
Zagidullin NS, Gareeva DF, Ishmetov VS, Pavlov AV, Plotnikova MR, Pushkareva AE, Pavlov VN. Renin-angiotensin-aldosterone system in new coronavirus infection 2019. Arter gipertenz 2020;26:240-7. [DOI: 10.18705/1607-419x-2020-26-3-240-247] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 65 |
Fisun AY, Cherkashin DV, Tyrenko VV, Zhdanov CV, Kozlov CV. Role of renin-angiotensin-aldosterone system in the interaction with coronavirus SARS-CoV-2 and in the development of strategies for prevention and treatment of new coronavirus infection (COVID-19). Arter gipertenz 2020;26:248-262. [DOI: 10.18705/1607-419x-2020-26-3-248-262] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 66 |
Wu L, O'Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Biochem Pharmacol. 2020;178:114114. [PMID: 32579957 DOI: 10.1016/j.bcp.2020.114114] [Cited by in Crossref: 63] [Cited by in F6Publishing: 44] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 67 |
Radenkovic D, Chawla S, Pirro M, Sahebkar A, Banach M. Cholesterol in Relation to COVID-19: Should We Care about It? J Clin Med 2020;9:E1909. [PMID: 32570882 DOI: 10.3390/jcm9061909] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 25.7] [Reference Citation Analysis]
|
| 68 |
de Vries AAF. Renin-angiotensin system inhibition in COVID-19 patients. Neth Heart J 2020;28:396-405. [PMID: 32514935 DOI: 10.1007/s12471-020-01439-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 69 |
Murray E, Tomaszewski M, Guzik TJ. Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications. Cardiovasc Res 2020;116:e87-9. [PMID: 32301968 DOI: 10.1093/cvr/cvaa096] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 70 |
Mahajan K, Chandra KS. Cardiovascular comorbidities and complications associated with coronavirus disease 2019. Med J Armed Forces India 2020;76:253-60. [PMID: 32773926 DOI: 10.1016/j.mjafi.2020.05.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 71 |
Moccia F, Gerbino A, Lionetti V, Miragoli M, Munaron LM, Pagliaro P, Pasqua T, Penna C, Rocca C, Samaja M, Angelone T. COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. Geroscience 2020;42:1021-49. [PMID: 32430627 DOI: 10.1007/s11357-020-00198-w] [Cited by in Crossref: 80] [Cited by in F6Publishing: 90] [Article Influence: 26.7] [Reference Citation Analysis]
|
| 72 |
Barison A, Aimo A, Castiglione V, Arzilli C, Lupón J, Codina P, Santiago-Vacas E, Cediel G, Emdin M, Bayes-Genis A. Cardiovascular disease and COVID-19: les liaisons dangereuses. Eur J Prev Cardiol 2020;27:1017-25. [PMID: 32391719 DOI: 10.1177/2047487320924501] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 73 |
Li Z, Liu T, Yang N, Han D, Mi X, Li Y, Liu K, Vuylsteke A, Xiang H, Guo X. Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain. Front Med. 2020;14:533-541. [PMID: 32367431 DOI: 10.1007/s11684-020-0786-5] [Cited by in Crossref: 142] [Cited by in F6Publishing: 159] [Article Influence: 47.3] [Reference Citation Analysis]
|
| 74 |
Zhou K, Yang S, Jia P. Towards precision management of cardiovascular patients with COVID-19 to reduce mortality. Prog Cardiovasc Dis 2020;63:529-30. [PMID: 32353374 DOI: 10.1016/j.pcad.2020.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 75 |
Gupta R. Letter to the editor in response to article: "Clinical considerations for patients with diabetes in times of COVID-19 epidemic (Gupta et al.). Diabetes Metab Syndr 2020;14:365. [PMID: 32330857 DOI: 10.1016/j.dsx.2020.04.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 76 |
Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M, Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Yuan Y, Loomba R, Liu PP, Li H. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020;126:1671-1681. [PMID: 32302265 DOI: 10.1161/circresaha.120.317134] [Cited by in Crossref: 650] [Cited by in F6Publishing: 826] [Article Influence: 216.7] [Reference Citation Analysis]
|
| 77 |
Li SR, Tang ZJ, Li ZH, Liu X. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV. Eur J Clin Microbiol Infect Dis 2020;39:1021-6. [PMID: 32285293 DOI: 10.1007/s10096-020-03883-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 16.7] [Reference Citation Analysis]
|
| 78 |
Messerli FH, Siontis GCM, Rexhaj E. COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations. Circulation 2020;141:2042-4. [PMID: 32282224 DOI: 10.1161/CIRCULATIONAHA.120.047022] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 79 |
Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142. [PMID: 32278764 DOI: 10.1016/j.diabres.2020.108142] [Cited by in Crossref: 372] [Cited by in F6Publishing: 271] [Article Influence: 124.0] [Reference Citation Analysis]
|
| 80 |
Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr 2020;14:283-7. [PMID: 32283499 DOI: 10.1016/j.dsx.2020.03.016] [Cited by in Crossref: 136] [Cited by in F6Publishing: 141] [Article Influence: 45.3] [Reference Citation Analysis]
|
| 81 |
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14:303-310. [PMID: 32298981 DOI: 10.1016/j.dsx.2020.04.004] [Cited by in Crossref: 431] [Cited by in F6Publishing: 445] [Article Influence: 143.7] [Reference Citation Analysis]
|
| 82 |
Gupta R, Misra A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). Diabetes Metab Syndr. 2020;14:251-254. [PMID: 32247213 DOI: 10.1016/j.dsx.2020.03.012] [Cited by in Crossref: 78] [Cited by in F6Publishing: 90] [Article Influence: 26.0] [Reference Citation Analysis]
|
| 83 |
Hussain A, do Vale Moreira NC. Clinical considerations for patients with diabetes in times of COVID-19 pandemic. Diabetes Metab Syndr 2020;14:451-3. [PMID: 32388324 DOI: 10.1016/j.dsx.2020.03.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 84 |
[DOI: 10.1101/2020.04.24.20077875] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
|
| 85 |
[DOI: 10.1101/2020.05.06.20093260] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
|
